astrocytoma, IDH-mutant, grade 4

Summary

astrocytoma, IDH-mutant, grade 4 (MONDO:0956981) is a disease and 10 clinical trials. Top therapeutic interventions include eflornithine, ipilimumab, and retifanlimab. A subtype of IDH-mutant anaplastic astrocytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	astrocytoma, IDH-mutant, grade 4
Mondo ID	MONDO:0956981
DOID	DOID:0080877
NCIT	C167335
UMLS	C5238471
MedGen	1718223
GARD	0026772
Is cancer (heuristic)	no

Data availability: 4 cell lines.

Disease family

This is a subtype of IDH-mutant anaplastic astrocytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astrocytic tumor › high grade astrocytic tumor › anaplastic astrocytoma › IDH-mutant anaplastic astrocytoma › astrocytoma, IDH-mutant, grade 4

Related subtypes (2): astrocytoma, IDH-mutant, grade 2, astrocytoma, IDH-mutant, grade 3

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	5
PHASE2	2
PHASE3	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05303519	PHASE3	RECRUITING	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT04145115	PHASE2	ACTIVE_NOT_RECRUITING	A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
NCT07301268	PHASE2	RECRUITING	GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
NCT07468136	PHASE1/PHASE2	NOT_YET_RECRUITING	Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
NCT05789394	PHASE1	RECRUITING	Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
NCT06815029	PHASE1	RECRUITING	Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
NCT06896110	PHASE1	ENROLLING_BY_INVITATION	Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
NCT07544992	PHASE1	RECRUITING	Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
NCT06860594	PHASE1	SUSPENDED	Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT06623565	Not specified	RECRUITING	Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EFLORNITHINE	4	1
IPILIMUMAB	4	1
RETIFANLIMAB	4	1
TRIAPINE	3	1
EFLORNITHINE, (S)-	2	1
SAFUSIDENIB	2	1
CHEMBL4446459	0	1